VAXART INC. - COMMON STOCK

Vaxart Provides Business Update and Reports Full Year 2023 Financial Results

14 Mar 2024 16:01:00 By Nasdaq GlobeNewswire

Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14

07 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director

06 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge

05 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

19 Jan 2024 08:30:00 By Nasdaq GlobeNewswire

Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management

16 Jan 2024 09:25:20 By Nasdaq GlobeNewswire

Vaxart, Inc. Announces Management Change

16 Jan 2024 09:22:58 By Nasdaq GlobeNewswire

Vaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers

21 Dec 2023 08:00:00 By Nasdaq GlobeNewswire

Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results

02 Nov 2023 16:01:22 By Nasdaq GlobeNewswire

Vaxart Doses First Subject in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers

02 Nov 2023 08:00:00 By Nasdaq GlobeNewswire

Vaxart to Host Third Quarter 2023 Business Update and Financial Results Conference Call on November 2

26 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

Vaxart to Present at World Vaccine Congress Europe 2023 on October 18-19

11 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

Vaxart to Participate in Fireside Chat at 2023 Cantor Global Healthcare Conference

21 Sep 2023 08:00:00 By Nasdaq GlobeNewswire

Vaxart Announces Topline Data from the Phase 2 Challenge Study of its Monovalent Norovirus Vaccine Candidate

06 Sep 2023 16:05:00 By Nasdaq GlobeNewswire

Vaxart Provides Business Update and Reports Second Quarter 2023 Financial Results

03 Aug 2023 16:01:00 By Nasdaq GlobeNewswire

Vaxart to Host Second Quarter 2023 Business Update and Financial Results Conference Call on August 3

27 Jul 2023 08:00:01 By Nasdaq GlobeNewswire

Vaxart Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2 Study of its Bivalent Norovirus Vaccine Candidate

06 Jul 2023 08:00:01 By Nasdaq GlobeNewswire

Vaxart Stockholders Approve All Four Proposals in the 2023 Proxy Statement

26 Jun 2023 16:45:00 By Nasdaq GlobeNewswire

Vaxart Encourages All Stockholders of Record as of April 28, 2023 to Vote by June 25, 2023, at 11:59 p.m. ET

21 Jun 2023 16:30:00 By Nasdaq GlobeNewswire

Vaxart, Inc. Announces Pricing of $15,000,000 Public Offering of Common Stock

07 Jun 2023 09:16:01 By Nasdaq GlobeNewswire